Antibacterial Efficacy of Eravacycline In Vivo against Gram-Positive and Gram-Negative Organisms

Abstract

Members of the tetracycline class are frequently classified as bacteriostatic. However, recent findings have demonstrated an improved antibacterial killing profile, often achieving ≥3 log10 bacterial count reduction, when such antibiotics have been given for periods longer than 24 h. We aimed to study this effect with eravacycline, a novel fluorocycline, given in an immunocompetent murine thigh infection model over 72 h against two methicillin-resistant Staphylococcus aureus (MRSA) isolates (eravacycline MICs = 0.03 and 0.25 μg/ml) and three Enterobacteriaceae isolates (eravacycline MICs = 0.125 to 0.25 μg/ml). A humanized eravacycline regimen, 2.5 mg/kg of body weight given intravenously (i.v.) every 12 h (q12h), demonstrated progressively enhanced activity over the 72-h study period. A cumulative dose response in which bacterial density was reduced by more than 3 log10 CFU at 72 h was noted over the study period in the two Gram-positive isolates, and eravacycline performed similarly to comparator antibiotics (tigecycline, linezolid, and vancomycin). A cumulative dose response with eravacycline and comparators (tigecycline and meropenem) over the study period was also observed in the Gram-negative isolates, although more variability in bacterial killing was observed for all antibacterial agents. Overall, a bacterial count reduction of ≥3 log was achieved in one of the three isolates with both eravacycline and tigecycline, while meropenem achieved a similar endpoint against two of the three isolates. Bactericidal activity is typically defined in vitro over 24 h; however, extended regimen studies in vivo may demonstrate an improved correlation with clinical outcomes by better identification of antimicrobial effects.

FIG 1

Efficacy of eravacycline, linezolid, tigecycline, and vancomycin at doses simulating human exposures against methicillin-resistant S. aureus 156 (MIC = 0.03 μg/ml) in an immunocompetent murine thigh infection model.

FIG 2

Efficacy of eravacycline, linezolid, tigecycline, and vancomycin at doses simulating human exposures against methicillin-resistant S. aureus 426 (MIC = 0.25 μg/ml) in an immunocompetent murine thigh infection model.

FIG 3

Efficacy of eravacycline, meropenem, and tigecycline at doses simulating human exposures against E. coli 373 (MIC = 0.25 μg/ml) in an immunocompetent murine thigh infection model.

FIG 4

Efficacy of eravacycline, meropenem, and tigecycline at doses simulating human exposures against C. freundii 26 (MIC = 0.125 μg/ml) in an immunocompetent murine thigh infection model.

FIG 5

Efficacy of eravacycline, meropenem, and tigecycline at doses simulating human exposures against E. coli C3-14 (MIC = 0.25 μg/ml) in an immunocompetent murine thigh infection model.